Connection

Daniele Focosi to Antibodies, Neutralizing

Back to Details
This is a "connection" page, showing publications Daniele Focosi has written about Antibodies, Neutralizing.
Daniele Focosi
Connection Strength
1.142
Antibodies, Neutralizing
  1. COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses. 2021 08 11; 13(8).
    View in: PubMed
    Score: 0.135
  2. An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future. Expert Opin Drug Discov. 2021 12; 16(12):1403-1414.
    View in: PubMed
    Score: 0.135
  3. Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment. Eur J Haematol. 2021 Jul; 107(1):24-28.
    View in: PubMed
    Score: 0.132
  4. Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies. Clin Microbiol Infect. 2021 Jul; 27(7):987-992.
    View in: PubMed
    Score: 0.132
  5. Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. Rev Med Virol. 2021 11; 31(6):e2231.
    View in: PubMed
    Score: 0.131
  6. COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review. Transfus Apher Sci. 2021 Jun; 60(3):103071.
    View in: PubMed
    Score: 0.130
  7. Viral infection neutralization tests: A focus on severe acute respiratory syndrome-coronavirus-2 with implications for convalescent plasma therapy. Rev Med Virol. 2021 03; 31(2):e2170.
    View in: PubMed
    Score: 0.127
  8. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs. 2020 Jan-Dec; 12(1):1854149.
    View in: PubMed
    Score: 0.121
  9. SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. Viruses. 2021 06 23; 13(7).
    View in: PubMed
    Score: 0.033
  10. Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency. Transfus Clin Biol. 2021 May; 28(2):132-134.
    View in: PubMed
    Score: 0.033
  11. Convalescent Plasma Therapy for COVID-19: State of the Art. Clin Microbiol Rev. 2020 09 16; 33(4).
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.